NASDAQ:ENGN enGene (ENGN) Stock Price, News & Analysis $1.74 -0.02 (-0.85%) As of 01:27 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About enGene Stock (NASDAQ:ENGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get enGene alerts:Sign Up Key Stats Today's Range$1.73▼$1.8050-Day Range$1.45▼$2.4152-Week Range$1.40▼$12.25Volume239,382 shsAverage Volume1.05 million shsMarket Capitalization$116.95 millionP/E RatioN/ADividend YieldN/APrice Target$10.75Consensus RatingModerate Buy Company Overview enGene is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. Read More enGene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreENGN MarketRank™: 4.038144895715 of 5 starsenGene scored higher than 81% of companies evaluated by MarketBeat, and ranked 66th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingenGene has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 7 buy ratings, 4 hold ratings, and 2 sell ratings.Upside PotentialenGene has a consensus price target of $10.75, representing about 513.2% upside from its current price of $1.75.Amount of Analyst CoverageenGene has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about enGene's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for enGene are expected to grow in the coming year, from ($1.82) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of enGene is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of enGene is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioenGene has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about enGene's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.71% of the float of enGene has been sold short.Short Interest Ratio / Days to CoverenGene has a short interest ratio ("days to cover") of 1.92, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in enGene has recently increased by 8.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldenGene does not currently pay a dividend.Dividend GrowthenGene does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.49 News SentimentenGene has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for enGene this week, compared to 8 articles on an average week.Search InterestOnly 1 people have searched for ENGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added enGene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $10,051.00 in company stock, which represents 0.0086% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, enGene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,051.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.50% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about enGene's insider trading history. Receive ENGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENGN Stock News HeadlinesHow Many Engine Hours Is Considered A Lot For A Kubota Standard L Series Tractor?November 19 at 1:40 AM | msn.comWhat is an EGR valve and how does it work in a diesel engine?November 17 at 12:24 AM | msn.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 20 at 1:00 AM | Behind the Markets (Ad)The Most Reliable Audi Engine You Can Get Going Into 2027 Sits In Just One AudiNovember 17 at 2:22 PM | msn.comenGene (NASDAQ:ENGN) Upgraded at Leerink PartnersNovember 16, 2026 | americanbankingnews.comEnGene Therapeutics (ENGN) Stock Gets Fair Value Boost After Analyst Views On LEGEND DataNovember 15, 2026 | finance.yahoo.comenGene (NASDAQ:ENGN) Raised to "Overweight" at Wells Fargo & CompanyNovember 14, 2026 | americanbankingnews.comPiper Sandler Upgrades enGene (NASDAQ:ENGN) to "Overweight"November 14, 2026 | americanbankingnews.comSee More Headlines ENGN Stock Analysis - Frequently Asked Questions How have ENGN shares performed this year? enGene's stock was trading at $9.03 on January 1st, 2026. Since then, ENGN stock has decreased by 80.6% and is now trading at $1.7530. How were enGene's earnings last quarter? enGene Holdings Inc. (NASDAQ:ENGN) released its quarterly earnings results on Tuesday, September, 8th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.04. How do I buy shares of enGene? Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings9/08/2026Today11/20/2026Next Earnings (Estimated)12/22/2026Fiscal Year End10/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ENGN's financial health is in the Red zone, according to TradeSmith. ENGN has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ENGN Previous SymbolNASDAQ:ENGN CIK1980845 Webwww.engene.com Phone(514) 332-4888FaxN/AEmployees82Year Founded1999Price Target and Rating Average Price Target for enGene$10.75 High Price Target$30.00 Low Price Target$2.00 Potential Upside/Downside+516.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$117.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-55.79% Return on Assets-45.17% Debt Debt-to-Equity Ratio0.11 Current Ratio10.21 Quick Ratio10.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.60 per share Price / Book0.67Miscellaneous Outstanding Shares67,020,000Free Float59,979,000Market Cap$116.95 million OptionableOptionable Beta-0.24 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ENGN) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.